The OncoMutations Panel is designed to detect mutations within oncogenes and tumor suppressor genes frequently mutated in human cancers. Diagnostic, prognostic, and predictive biologic markers in this panel are important in personalizing cancer care. The result of this test may guide a patient to the appropriate chemotherapy or clinical trial. OncoMutations Panel targets ~2800 mutations in the following 49 key cancer genes: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL.1,2,3,4
Smaller gene panels and single gene assays are available for some of these targets. Also available is an expanded panel (OncoMutations PLUS OncoFusions) which additionally detects fusion transcripts involving 53 genes commonly rearranged in solid tumors: AKT3, ALK, ARHGAP26, AXL, BRAF, BRD3, BRD4, EGFR, ERG, ESR1, ETV1, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FGR, INSR, MAML2, MAST1 MAST2 MET MSMB, MUSK, MYB, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PDGFRA, PDGFRB, PIK3CA, PKN1, PPARG, PRKCA, PRKCB, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, TERT, TFE3, TFEB, THADA, TMPRSS2
To open a printable assay summary in a new window, click the link below.
(Targeted analysis of ~2800 COSMIC mutations of oncogenes and tumor suppressor genes frequently mutated in human cancers)
(in portable document format (pdf) which requires Adobe® Acrobat® Reader™ to view or print; download latest version free)
- Rothberg JM, et al; An integrated semiconducted device enabling non-optical genome sequencing. Nature, 2011 Jul20; 475(7356):348-52
- Dancey JE, et al; The genetic basis for cancer treatment decisions. Cell, 2012 Feb 3; 148(3): 409-20. Review